A smart inhaler is only as good as the numbers it records. RS01X measures each inhalation as it happens — its duration, its volume and the peak inspiratory flow behind it — and those measurements are what every adherence and technique insight is later built on. So the first question a pharmaceutical or clinical partner should ask is the plainest one: are they accurate?
A study set out to answer it: first presented at the Respiratory Drug Delivery (RDD) 2024 conference, then published, peer-reviewed, in the International Journal of Chronic Obstructive Pulmonary Disease. Researchers compared RS01X's on-device readings against an external inhalation-profile recorder, the laboratory reference for this kind of measurement, across 97 participants: 32 with asthma, 30 with COPD and 35 with healthy lungs, over 291 inhalations.
Agreement between the device and the reference was near-perfect: an intraclass correlation above 0.95 for every parameter measured (duration, volume and peak inspiratory flow), all highly significant. The only meaningful differences appeared when participants deliberately used the inhaler incorrectly, holding it at an angle rather than level, and RS01X registered that too.
Why measurement accuracy is the foundation
This is a validation of the device's measurements, not a study of patient outcomes, and that distinction matters. It doesn't claim RS01X makes people better; it shows that the data RS01X produces can be trusted. For a partner deciding whether to build an evidence programme on connected-inhaler data, that is the groundwork everything else rests on: adherence scoring, technique feedback, the real-world evidence a therapy is measured by. None of it holds if the underlying readings drift.
"Connected care only works if the measurements underneath it are trustworthy. An independent validation like this is the part you have to get right before anything built on the data means anything."
Martijn Grinovero, Chief Commercial Officer, Amiko
RS01X keeps the proven RS01 mechanism, Plastiape's widely used single-dose dry-powder inhaler, and builds Respiro's sensing in around it. This validation is the evidence that the sensing does its job with the precision a regulated programme needs. The full study, and the rest of the evidence behind Respiro, sits on our evidence page.
Source: Chamaon D, Sportel E, Elferink ECM, van der Palen J. Validation of an AI-Powered Smart Dry Powder Inhaler (RS01X) for Asthma and COPD in a Clinical Setting. Int J Chron Obstruct Pulmon Dis. 2025;20:811–819. doi:10.2147/COPD.S490684. Peer-reviewed; n=97. The findings were first presented at Respiratory Drug Delivery (RDD) 2024 and published in peer-reviewed form in 2025. This study validated the accuracy of the device's measurements; it is not a claim of treatment efficacy or individual outcomes.